Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$174M in Q4 2024 → $534M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Meiragtx Holdings PLC | 30.9% | Unchanged | 12,197,737 | $165M |
| Inhibrx Biosciences, Inc. | 20.5% | Unchanged | 1,157,926 | $110M |
| Novavax | 12.1% | Unchanged | 6,880,481 | $64.8M |
| Anaptysbio | 10.4% | Unchanged | 821,917 | $55.5M |
| Odyssey Therapeutics Inc. | 7.0% | New | 1,991,918 | $37.3M |
| Agomab Therapeutics Nv | 6.8% | Unchanged | 2,783,096 | $36.1M |
| Maplight Therapeutics Inc. | 6.1% | Unchanged | 912,041 | $32.7M |
| First Tracks Biotherapeutics Inc. | 3.1% | New | 821,917 | $16.5M |
| Immuneering Corp | 2.5% | Unchanged | 2,708,559 | $13.5M |
| Q32 Bio Inc. | 0.6% | Unchanged | 244,083 | $3.11M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed July 28, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Odyssey Therapeutics Inc. | New | +1,991,918 | +$37.3M | 7.0% |
| First Tracks Biotherapeutics Inc. | New | +821,917 | +$16.5M | 3.1% |
| E Eledon | Exited | −814,980 | −$2.51M | — |
quarter ended March 31, 2026 · filed May 07, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Agomab Therapeutics Nv | New | +2,783,096 | +$29.2M | 8.7% |
quarter ended December 31, 2025 · filed February 11, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Maplight Therapeutics Inc. | New | +912,041 | +$16M | 5.2% |
| Omada Health Inc. | Exited | −524,903 | −$11.6M | — |
| LT Lava Therapeutics N.v. | Exited | −1,919,455 | −$2.99M | — |
quarter ended September 30, 2025 · filed November 04, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Immuneering Corp | New | +2,708,559 | +$19M | 7.3% |
| I Inozyme, Inc | Exited | −443,255 | −$1.77M | — |
| Igm Biosciences | Exited | −1,438,975 | −$1.61M | — |
quarter ended June 30, 2025 · filed July 29, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Omada Health Inc. | New | +524,903 | +$9.61M | 5.5% |
quarter ended March 31, 2025 · filed May 06, 2025
No position changes this quarter.
Loading...
